Ocular Therapeutix advances sustained-release products through pipeline

LAS VEGAS — Ocular Therapeutix is in the broad and late-stages of the pipelines for its anterior and posterior sustained-release therapies, according to a presentation here. “Every year we have a lot of advances, a lot of status updates to show where we are,” Amar Sawhney, president and CEO of Ocular Therapeutix, said at a company media briefing at the American Academy of Ophthalmology annual meeting. “What we are hoping to accomplish is to transform eye care using sustained therapies.”